Sign in

CIK 0001677077 · <br>Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
operating
EIN
811822909
Phone
844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 8-K Event Delisting notice
  2. 4 Open-market buy 10% owner bought 10,000 shares at $0.88 ($8,841)
  3. 4 Open-market buy 10% owner bought 10,000 shares at $0.87 ($8,740)
  4. 4 Open-market buy 10% owner bought 10,000 shares at $0.85 ($8,474)
  5. 4 Open-market buy 10% owner bought 8,000 shares at $0.95 ($7,576)
  6. 4 Open-market buy 10% owner bought 2,000 shares at $0.94 ($1,881)
  7. 8-K Event Regulation FD disclosure
  8. 4 Open-market buy 10% owner bought 8,000 shares at $0.96 ($7,679)
  9. 4 Open-market buy 10% owner bought 22,000 shares at an average $0.94 ($20,627)
  10. 4 Open-market buy 10% owner bought 16,100 shares at $0.89 ($14,306)
  11. 4 Other acquisition 10% owner acquired 3,900 shares (other)
  12. 4 Open-market buy 10% owner bought 23,900 shares at $0.98 ($23,343)
  13. 4 Open-market buy 10% owner bought 125,000 shares at an average $0.97 ($121,298)
  14. 4 Open-market buy 10% owner bought 100,000 shares at $1.07 ($106,850)
  15. 4 Open-market buy 10% owner bought 2,666,667 shares at $1.50 ($4,000,001)
  16. 4 Option exercise Director acquired 250,000 shares (option exercise)
  17. SC 13D/A Stake Beneficial Ownership Report
  18. 4 Open-market buy 10% owner bought 75,000 shares at $0.94 ($70,335)
  19. 8-K/A Event Regulation FD disclosure · Other events
  20. 8-K Event Regulation FD disclosure

Page 12 of 20 · 398 filings